# OnCo record clear-cell-rcc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/clear-cell-rcc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "clear-cell-rcc" ;
  schema:name "Clear cell renal cell carcinoma"@en ;
  schema:alternateName "KIRC"@en, "TCGA-KIRC"@en, "kidney renal clear cell carcinoma (TCGA KIRC cohort)"@en, "ccRCC"@en, "Conventional renal cell carcinoma"@en ;
  schema:description "Clear cell is the common kidney cancer, driven by loss of the VHL gene that leaves the tumour behaving as if starved of oxygen and flooding itself with blood vessels. That biology explains why anti-angiogenic drugs, immunotherapy and the HIF-2 alpha blocker belzutifan all work."@en ;
  schema:url <https://onco.cc/cancers/clear-cell-rcc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Clear-cell_renal_cell_carcinoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Clear-cell_renal_cell_carcinoma> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/chromophobe-rcc/>, <https://onco.cc/cancers/papillary-rcc/> ;
  onco:terms <https://onco.cc/terms/bap1-loss/> ;
  onco:trials <https://onco.cc/trials/carmena/>, <https://onco.cc/trials/checkmate-025/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-564-nejm-2021/>, <https://onco.cc/key-papers/paper-clear-nejm-2021/>, <https://onco.cc/key-papers/paper-keynote-426-nejm-2019/>, <https://onco.cc/key-papers/paper-checkmate-214-nejm-2018/> ;
  onco:pipeline <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/targets/hif2a/> ;
  onco:standardOfCare <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/terms/cryoablation/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-564/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/keynote-426/>, <https://onco.cc/trials/checkmate-214/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/targets/hif2a/>, <https://onco.cc/drugs/belzutifan/> .